close

Fundraisings and IPOs

1 59 60 61 62 63 65
Number of results: 1292
Date Company Amount Funding type Investors Therapeutic area Type of Information
2011-06-24 Neovacs (France) € 420 000 capital increase via the issuance independent of preemption rights of 105,500 shares. The shares were placed with 3 investors. Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Capital increase
2011-06-23 Scil Technology (Germany) € 0.9 million grant Federal Ministry of Education and Research (BMBF)(Germany) Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Grant
2011-06-21 Shield Therapeutics (UK) €8.2m (CHF10m/US$12m) series A financing round Inventages Venture Capital Fundraising
2011-06-17 TcLand Expression (France) € 1.2 million french and european grants Oseo (France) - European Regional Development Fund (ERDF) Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Grant
2011-06-13 Neovacs (France) €7.6 million The capital increase took place via a private placing, The shares were placed with 37 investors. Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Capital increase
2011-06-13 Haemostatix (UK) £250,000 (€284,000) financing round Esperante Ventures (UK) Technology - Services - Hemostasis Fundraising
2011-06-13 BliNK Therapeutics (UK) up to £1.1m as seed financing, the investment to start-up the company, and up to £6.6m in further financing seed financing Cancer Research Technology (UK) - Kurma Life Sciences Partners (France) Fundraising
2011-06-09 Neovacs (France) €1,448 million OSEO (France) Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Grant
2011-06-01 Bioinvent International (Sweden) SEK 136 million (€15.16 million) private placement Cancer - Oncology Private placement
2011-06-01 Swedish Orphan Biovitrum - SOBI (Sweden) SEK 637 million (€71 million) rights issue Rare diseases - Genetic diseases Private placement
2011-06-01 Shield Therapeutics (UK) €8.2 million series A financing round Inventages Venture Capital  (UK-Switzerland-New Zealand-Bahamas) Fundraising
2011-05-31 Tigenix (Belgium) € 15.2 million capital increase Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Capital increase
2011-05-30 Clavis Pharma (Norway) NOK 14 million (€ 1.8 million) grant The Research Council of Norway Cancer - Oncology Grant
2011-05-27 Synairgen (UK) £2.65 million (€3 million) private placement Allergic diseases - Inflammatory diseases - Respiratory diseases Private placement
2011-05-24 Genkyotex (Switzerland) CHF 18 million (€14.5 million) series C financing round Edmond de Rothschild Investment Partners (EdRIP) (France) - Vesalius Biocapital Partners (Luxembourg) - MP Healthcare Venture Management (USA) - Eclosion (Switzerland) - SEFTI SGAM (France) - Fondation d’Aide aux Entreprises (FAE) Cardiovascular diseases - Metabolic diseases - Respiratory diseases - Inflammatory diseases - Autoimmune diseases Fundraising
2011-05-20 ACS Biomarker (The Netherlands) undisclosed financing round Life Sciences Fund Amsterdam (The Netherlands)
Limburg Ventures (The Netherlands)
Cardiovascular diseases Fundraising
2011-05-19 Q Chip (UK) $6 million (£3.6 million - €4.2 million) Series C financing round Limburg Ventures (The Netherlands) - Nedermaas Hightech Ventures  (The Netherlands) - Disruptive Capital Finance (UK) - Finance Wales UK) - an “Angel” syndicate of highly experienced individual investors including Q Chip’s Executive Chairman and biotech entrepreneur Ken Powell, British venture capitalist Jon Moulton and industrial entrepreneur Sir Harry Solomon Cancer - Oncology Fundraising
2011-05-18 Themis Bioscience (Austria) €5 million series A financing round Crédit Agricole Private Equity (France) - Ventech (France) Infectious diseases Fundraising
2011-05-17 Curetis (Germany) € 24.5 million series A venture equity investment round aeris Capital - LSP Life Sciences Partners (The Netherlands) - BioMedInvest (Switzerland) - KfW (Germany) - CD-Venture (Germany) - Private investors Technology - Services - Infectious diseases Fundraising
2011-05-13 Advicenne Pharma (France) €5.1 million venture capital Innobio (France) - IXO Private Equity (France) - Private investors CNS diseases - Renal diseases Fundraising